Latest News, Updates & Breaking Headlines
NEW DELHI: India’s pharmaceutical industry must focus on both generics and innovative products, as well as develop products specially tailored for the country’s patient needs. Domestic companies particularly smaller to mid-sized players can carve out a strong role in rare diseases and niche patient segments, where agility and specialised research can drive meaningful breakthroughs, pharma…
The impending patent expiry of semaglutide drugs across India, emerging markets and select regulated markets such as Canada and Brazil is expected to create a revenue opportunity of more than Rs 50 billion for generic pharmaceutical companies over the next 12 to 15 months, according to an industry update by Systematix Institutional Research.The report said…
US President Donald Trump‘s announcement of a 100% tariff on imported “branded and patented pharmaceutical products” has rattled the global pharma industry, though Indian generic drug makers are largely expected to remain unaffected for now.Trump, in a post on Truth Social on Thursday, stated: “Starting October 1st, 2025, we will be imposing a 100% Tariff…
